🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06898281
Active, not recruiting Not applicable

Intracardiac Echocardiography-Guided Catheter Ablation for Premature Ventricular Contractions Originating From the Papillary Muscles

NCT06898281 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Chest Hospital
Phase
Not applicable
Started
2025-03-23
Last updated
2025-04-24

Condition(s) studied

Premature Ventricular Contractions

Investigational drug(s) / intervention(s)

intracardiac echocardiography (ICE)-guided catheter ablationPressure-sensing catheter ablation alone

intracardiac echocardiography (ICE)-guided catheter ablation: Intracardiac echocardiography (ICE)-guided catheter ablation.

Pressure-sensing catheter ablation alone: Pressure-sensing catheter ablation alone

Study summary

This randomized, prospective, parallel, single-blind, multicenter clinical trial investigates the efficacy and safety of intracardiac echocardiography (ICE)-guided catheter ablation versus pressure-sensing catheter ablation alone in reducing PVC recurrence among patients with confirmed papillary muscle-originating premature ventricular contractions (PVCs). Participants were randomly allocated to either the ICE-guided intervention group or the conventional ablation control group following definitive diagnosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Patients aged ≥18 years. * Diagnosed with premature ventricular contractions (PVCs) originating from the papillary muscles. * Symptoms refractory to antiarrhythmic drug therapy. * Patients must be capable and willing to provide written informed consent for study participation. Exclusion Criteria: * History of cardiac surgery or any prior cardiac interventional procedures. * Ischemic heart disease, dilated cardiomyopathy, or hypertrophic cardiomyopathy. * Severe hepatic or renal dysfunction: AST/ALT \>3× upper limit of normal (ULN); Serum creatinine (SCr) \>3.5 mg/dl or creatinine clearance (Ccr) \<30 ml/min. * Prior ablation for papillary muscle PVCs. * Life expectancy \<1 year. * Pregnancy or lactation.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Chest Hospital Shanghai Xuhui

More Shanghai Chest Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06898281 on ClinicalTrials.gov ↗ ← All trials in China